Cargando…

Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes death within a mean of 2–3 years from symptom onset. There is no diagnostic test and the delay from symptom onset to diagnosis averages 12 months. The identification of prognostic and diagnostic biomarkers in ALS would fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayatti, Nadhim, Cooper-Knock, Johnathan, Bury, Joanna J., Wyles, Matthew, Heath, Paul R., Kirby, Janine, Shaw, Pamela J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903649/
https://www.ncbi.nlm.nih.gov/pubmed/24475299
http://dx.doi.org/10.1371/journal.pone.0087508
_version_ 1782301130468884480
author Bayatti, Nadhim
Cooper-Knock, Johnathan
Bury, Joanna J.
Wyles, Matthew
Heath, Paul R.
Kirby, Janine
Shaw, Pamela J.
author_facet Bayatti, Nadhim
Cooper-Knock, Johnathan
Bury, Joanna J.
Wyles, Matthew
Heath, Paul R.
Kirby, Janine
Shaw, Pamela J.
author_sort Bayatti, Nadhim
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes death within a mean of 2–3 years from symptom onset. There is no diagnostic test and the delay from symptom onset to diagnosis averages 12 months. The identification of prognostic and diagnostic biomarkers in ALS would facilitate earlier diagnosis and faster monitoring of treatments. Gene expression profiling (GEP) can help to identify these markers as well as therapeutic targets in neurological diseases. One source of genetic material for GEP in ALS is peripheral blood, which is routinely accessed from patients. However, a high proportion of globin mRNA in blood can mask important genetic information. A number of methods allow safe collection, storage and transport of blood as well as RNA stabilisation, including the PAXGENE and TEMPUS systems for the collection of whole blood and LEUKOLOCK which enriches for the leukocyte population. Here we compared these three systems and assess their suitability for GEP in ALS. We collected blood from 8 sporadic ALS patients and 7 controls. PAXGENE and TEMPUS RNA extracted samples additionally underwent globin depletion using GlobinClear. RNA was amplified and hybridised onto Affymetrix U133 Plus 2.0 arrays. Lists of genes differentially regulated in ALS patients and controls were created for each method using the R package PUMA, and RT-PCR validation was carried out on selected genes. TEMPUS/GlobinClear, and LEUKOLOCK produced high quality RNA with sufficient yield, and consistent array expression profiles. PAXGENE/GlobinClear yield and quality were lower. Globin depletion for PAXGENE and TEMPUS uncovered the presence of over 60% more transcripts than when samples were not depleted. TEMPUS/GlobinClear and LEUKOLOCK gene lists respectively contained 3619 and 3047 genes differentially expressed between patients and controls. Real-time PCR validation revealed similar reliability between these two methods and gene ontology analyses revealed similar pathways differentially regulated in disease compared to controls.
format Online
Article
Text
id pubmed-3903649
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39036492014-01-28 Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis Bayatti, Nadhim Cooper-Knock, Johnathan Bury, Joanna J. Wyles, Matthew Heath, Paul R. Kirby, Janine Shaw, Pamela J. PLoS One Research Article Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes death within a mean of 2–3 years from symptom onset. There is no diagnostic test and the delay from symptom onset to diagnosis averages 12 months. The identification of prognostic and diagnostic biomarkers in ALS would facilitate earlier diagnosis and faster monitoring of treatments. Gene expression profiling (GEP) can help to identify these markers as well as therapeutic targets in neurological diseases. One source of genetic material for GEP in ALS is peripheral blood, which is routinely accessed from patients. However, a high proportion of globin mRNA in blood can mask important genetic information. A number of methods allow safe collection, storage and transport of blood as well as RNA stabilisation, including the PAXGENE and TEMPUS systems for the collection of whole blood and LEUKOLOCK which enriches for the leukocyte population. Here we compared these three systems and assess their suitability for GEP in ALS. We collected blood from 8 sporadic ALS patients and 7 controls. PAXGENE and TEMPUS RNA extracted samples additionally underwent globin depletion using GlobinClear. RNA was amplified and hybridised onto Affymetrix U133 Plus 2.0 arrays. Lists of genes differentially regulated in ALS patients and controls were created for each method using the R package PUMA, and RT-PCR validation was carried out on selected genes. TEMPUS/GlobinClear, and LEUKOLOCK produced high quality RNA with sufficient yield, and consistent array expression profiles. PAXGENE/GlobinClear yield and quality were lower. Globin depletion for PAXGENE and TEMPUS uncovered the presence of over 60% more transcripts than when samples were not depleted. TEMPUS/GlobinClear and LEUKOLOCK gene lists respectively contained 3619 and 3047 genes differentially expressed between patients and controls. Real-time PCR validation revealed similar reliability between these two methods and gene ontology analyses revealed similar pathways differentially regulated in disease compared to controls. Public Library of Science 2014-01-27 /pmc/articles/PMC3903649/ /pubmed/24475299 http://dx.doi.org/10.1371/journal.pone.0087508 Text en © 2014 Bayatti et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bayatti, Nadhim
Cooper-Knock, Johnathan
Bury, Joanna J.
Wyles, Matthew
Heath, Paul R.
Kirby, Janine
Shaw, Pamela J.
Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis
title Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis
title_full Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis
title_fullStr Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis
title_full_unstemmed Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis
title_short Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis
title_sort comparison of blood rna extraction methods used for gene expression profiling in amyotrophic lateral sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903649/
https://www.ncbi.nlm.nih.gov/pubmed/24475299
http://dx.doi.org/10.1371/journal.pone.0087508
work_keys_str_mv AT bayattinadhim comparisonofbloodrnaextractionmethodsusedforgeneexpressionprofilinginamyotrophiclateralsclerosis
AT cooperknockjohnathan comparisonofbloodrnaextractionmethodsusedforgeneexpressionprofilinginamyotrophiclateralsclerosis
AT buryjoannaj comparisonofbloodrnaextractionmethodsusedforgeneexpressionprofilinginamyotrophiclateralsclerosis
AT wylesmatthew comparisonofbloodrnaextractionmethodsusedforgeneexpressionprofilinginamyotrophiclateralsclerosis
AT heathpaulr comparisonofbloodrnaextractionmethodsusedforgeneexpressionprofilinginamyotrophiclateralsclerosis
AT kirbyjanine comparisonofbloodrnaextractionmethodsusedforgeneexpressionprofilinginamyotrophiclateralsclerosis
AT shawpamelaj comparisonofbloodrnaextractionmethodsusedforgeneexpressionprofilinginamyotrophiclateralsclerosis